Research
Hormonal
Classical anti-obesity agents (orlistat, phentermine-topiramate, naltrexone-bupropion) typically achieve only modest weight loss (3-10%) and are limited by tolerability and safety concerns.
Orlistat is an older, oral weight loss medication that helps block fat absorption. It typically leads to modest weight loss (3-5%) and can cause gastrointestinal side effects like oily stools. It is generally reserved for patients who cannot access or tolerate newer, more effective injectable therapies.
GoodQualifiesHIGH confidence
Classical agents such as orlistat, phentermine–topiramate and naltrexone–bupropion typically achieve 3–10% weight loss but are limited by tolerability and safety concerns.
Why this rating
Based on narrative review of multiple trials.
Source
Modern pharmacotherapy of obesity: molecular mechanisms, clinical efficacy and future therapeutic directions
Navneeth Selvan · International Journal of Basic & Clinical Pharmacology · 2026
DOI 10.18203/2319-2003.ijbcp20260443
narrative_reviewCited 1×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- Modern incretin-based and multi-agonist peptide therapies (GLP-1, GIP/GLP-1, and triple agonists) induce double-digit percentage weight loss (15-25%) that approaches or exceeds outcomes historically associated with bariatric surgery.Strong
- Semaglutide 2.4 mg significantly reduces major adverse cardiovascular events (MACE) in individuals with overweight or obesity without diabetes, establishing pharmacological weight loss as cardiovascular risk-modifying therapy.Strong
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →